用N-棕甲基胺治疗已确定的化疗诱导的神经病变:一个随机的,双盲的II期试点研究
Mellar P Davis1, Angela Ulrich2, Rebecca Segal3
1Levine Cancer Center, Charlotte, NC 28204, USA.
Cancers
|January 8, 2025
概括
在一项随机试验中,棕乙烯胺 (PEA) 并没有改善化疗诱导的外周神经病变 (CIPN). 需要进一步的研究来探索PEA.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗诱导的周围神经病变 (CIPN) 是一种常见的,使人衰弱的副作用,治疗方法,如氧沙和taxanes.
- 棕甲基乙醇胺 (PEA) 已显示出在疼痛性CIPN中改善髓化神经纤维功能的潜力.
- 已建立的CIPN存在重大临床挑战,需要有效的治疗干预措施.
研究的目的:
- 评估Palmitoylethanolamide (PEA) 在治疗已确定的化疗诱导的周围神经病变 (CIPN) 的疗效.
- 评估PEA对CIPN患者疼痛,麻木,刺痛和生活质量的影响.
- 确定PEA在已确定的CIPN患者中的安全性和耐受性.
主要方法:
- 进行了一项双盲,安慰剂控制,随机化试验.
- 纳入了长达至少三个月的CIPN症状的成年患者.
- 参与者接受了PEA或安慰剂8周,每周使用CIPN20问卷进行评估.
主要成果:
- 与安慰剂相比,在PEA组中没有观察到CIPN症状的显著改善.
- 生命质量和认知功能的结果在所有研究部门都是相似的.
- 在PEA和安慰剂治疗之间没有报告有显著的毒性差异.
结论:
- 棕甲基乙醇胺 (PEA) 没有在改善已建立的化疗诱导的周围神经病变 (CIPN) 中表现出有效性.
- 未来的研究可以调查PEA在预防CIPN或相关认知变化的潜在作用.
- 根据目前的试验结果,不建议PEA用于治疗现有的CIPN.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
219
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
219
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
201
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
201
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215


